Hospitals are seeing success treating multiple myeloma with advanced therapies. Second autologous stem cell transplants, even ...

The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), ...

The proposed recommendations are intended to safely expedite approvals of promising therapies for multiple myeloma, but one expert is skeptical about the likelihood of industry compliance.

"Very few patients in earlier years underwent two stem cell transplants and survived long-term. Today, with newer drugs such as daratumumab, carfilzomib, and bispecific antibodies like teclistamab, we ...

Experts discuss the importance of transitioning cancer care from academic centers to community settings, ensuring effective ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan. 2 in Blood.

Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat patients early after relapse.

Real world data show multiple myeloma survival varies by treatment line and autologous stem cell transplant status. Read more.

Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.

Darzalex Faspro improved PFS and OS in high-risk smoldering multiple myeloma, reducing progression or death risk by 51% and death risk by 48%. The AQUILA study showed a superior overall response rate ...

Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...